Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22345715 | 0.91 | ATM (0.46) | ALDH1A1ATMKMT2AMEN1POLB | |
| SCHEMBL22345716 | 0.91 | ATM (0.46) | ALDH1A1ATMKMT2AMEN1POLB | |
| SCHEMBL29647507 | 0.74 | SIGMAR1 (0.33) | — | |
| SCHEMBL10276800 | 0.74 | ATM (0.49) | CYP2D6CYP2C9CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL22360604 | 0.73 | CYP2D6 (0.56) | CYP2D6CYP2C9CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL22360516 | 0.73 | RAB9A (0.44) | ALDH1A1RAB9A | |
| SCHEMBL22360567 | 0.73 | RAB9A (0.44) | ALDH1A1RAB9A | |
| SCHEMBL29201725 | 0.72 | CYP2D6 (0.58) | CYP2D6CYP2C9CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL29647550 | 0.72 | EPHX2 (0.32) | — | |
| SCHEMBL10313031 | 0.72 | CYP2D6 (0.55) | CYP2D6CYP2C9CYP3A4CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214954-A1 | METHODS OF TREATING HIV USING TRITERPENE DERIVATIVES | HETERO LABS LIMITED (IN) | 2025-07-03 | — | — | US | disclosed |
| US-12275712-B2 | Triterpene derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2025-04-15 | — | — | US | disclosed |
| EP-4248960-A2 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | Hetero Labs Limited (IN) | 2023-09-27 | — | — | EP | disclosed |
| EP-3924361-B1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LTD (IN) | 2023-09-06 | — | — | EP | disclosed |
| US-20220177439-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177439-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | CYP51A1, CCR5, HSD17B7 | CYP2D6 786/4885CYP2C9 791/4885CYP3A4 37/4885 |
| US-12275712-B2 | Triterpene derivatives as HIV inhibitors | CCR5, CYP51A1, CYP4A11 | CYP2D6 361/4885CYP2C9 256/4885CYP3A4 16/4885 |
| US-20250214954-A1 | METHODS OF TREATING HIV USING TRITERPENE DERIVATIVES | CCR5, HSD17B7, CYP51A1 | CYP2D6 296/4885CYP2C9 546/4885CYP3A4 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.